Intelligent Bio Solutions Inc. has announced the release of a video detailing the initial results of its Pharmacokinetic (PK) study, which is a step towards an FDA 510(k) submission. The video was made available on November 20, 2024, on the company's website. Additionally, the company disclosed that it has successfully raised approximately $250,802 net of commissions through its At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. This capital raise was executed in two phases, with $34,511 net raised from September 18 to September 30, 2024, and $216,291 net from October 1 to November 19, 2024. The funds were raised through the sale of common stock, with the latest update provided as of November 19, 2024. The company's Chief Financial Officer, Spiro Sakiris, signed off on the report on November 20, 2024.

Intelligent Bio Solutions Inc. has announced the release of a video detailing the initial results of its Pharmacokinetic (PK) study, which is a step towards an FDA 510(k) submission. The video was made available on November 20, 2024, on the company's website. Additionally, the company disclosed that it has successfully raised approximately $250,802 net of commissions through its At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. This capital raise was executed in two phases, with $34,511 net raised from September 18 to September 30, 2024, and $216,291 net from October 1 to November 19, 2024. The funds were raised through the sale of common stock, with the latest update provided as of November 19, 2024. The company's Chief Financial Officer, Spiro Sakiris, signed off on the report on November 20, 2024.